<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831580</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-3043</org_study_id>
    <nct_id>NCT04831580</nct_id>
  </id_info>
  <brief_title>A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer</brief_title>
  <acronym>ROCC</acronym>
  <official_title>A Phase III Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GOG Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intuitive Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III randomized controlled trial to compare survival for patients who undergi&#xD;
      robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for&#xD;
      the treatment of early stage cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, multi-center, open-label, randomized, non-inferiority clinical trial&#xD;
      with the hypothesis that robotically assisted radical hysterectomy with tumor containment&#xD;
      prior to colpotomy is non-inferior to abdominal radical hysterectomy with respect to disease&#xD;
      free survival.&#xD;
&#xD;
      A t the commencement of surgery, a thorough inspection of all peritoneal surfaces should be&#xD;
      performed. The location of any suspected metastatic disease should be documented in the&#xD;
      operative report and a biopsy should be performed to confirm the diagnosis. If&#xD;
      intraperitoneal disease is detected, the radical hysterectomy should be abandoned. In&#xD;
      patients with macroscopic evidence of metastatic disease to the lymph nodes, intraoperative&#xD;
      frozen section should be performed to confirm the presence of metastatic disease.&#xD;
      Intraoperative management will be left to the discretion of the surgeon. Patients who have&#xD;
      confirmed macroscopic lymph node metastases intraoperatively will be excluded from final&#xD;
      analysis and replaced due to the controversy surrounding the decision to perform a radical&#xD;
      hysterectomy in this setting. Patients in whom the radical hysterectomy is abandoned will be&#xD;
      deemed non-evaluable and excluded from final analysis and will be replaced. For all patients,&#xD;
      the surgeon should document operative time from incision to close, detailed description of&#xD;
      operative findings, intraoperative complications, and blood loss. For patients randomized to&#xD;
      the robotic arm, the surgeon should document the use of and specify the type of vaginal&#xD;
      manipulator and the reason for conversion to laparotomy (if applicable). Transcervical&#xD;
      manipulators are not permitted.&#xD;
&#xD;
      Standard arm: Radical hysterectomy is performed as per standard technique (peon radical&#xD;
      hysterectomy (Piver type 2 or 3 or Querleu &amp; Morrow Type B or C) with salpingectomy +/-&#xD;
      oophorectomy. Ovaries may be removed or preserved +/- transposition. Prior to colpotomy, the&#xD;
      vagina must be closed over the tumor (ie, Wertheim clamps, contour stapling device).&#xD;
&#xD;
      Study arm: Radical hysterectomy is performed as per standard robotic technique (Querleu &amp;&#xD;
      Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved&#xD;
      +/- transposition. Colpotomy may be made intracorporally or vaginally. Vagina must be closed&#xD;
      prior to intracorporeal colpotomy (see below, #10)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>36 months</time_frame>
    <description>3 year disease-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Open radical hysterectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Robotic radical hysterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>da Vinci</intervention_name>
    <description>Minimally invasive robotic-assisted surgical device</description>
    <arm_group_label>Robotic radical hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>open surgery</intervention_name>
    <description>open radical hysterectomy</description>
    <arm_group_label>Open radical hysterectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma (usual/classic/NOS), squamous cell carcinoma,&#xD;
             adenosquamous carcinoma (Including glassy cell)&#xD;
&#xD;
          2. FIGO Stage IA2, IBI, IB2 (2018 staging) without evidence of definitive parametrial,&#xD;
             vaginal, nodal or distant metastases on exam or imaging.&#xD;
&#xD;
          3. Uterine size &lt;12 cm AND felt to be appropriate for vaginal delivery of the specimen&#xD;
&#xD;
          4. Suitable surgical candidate&#xD;
&#xD;
          5. Age 18 years or older&#xD;
&#xD;
          6. ECOG performance status 0-1&#xD;
&#xD;
          7. Adequate bone marrow, renal and hepatic function&#xD;
&#xD;
          8. Negative urine pregnancy test within 30 days of surgery in pre-menopausal women or&#xD;
             those &lt;2 years after onset of menopause&#xD;
&#xD;
          9. Prior malignancy allowed if &gt;5 years since diagnosis without evidence of disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any tumor histology other than those listed above&#xD;
&#xD;
          2. FIGO stage 1A1, IB3, II-IV (2018 staging)&#xD;
&#xD;
          3. Inability to have an MRI&#xD;
&#xD;
          4. Tumor size â‰¥4cm or evidence of definitive vaginal/parametrial involvement on pelvic&#xD;
             exam or MRI&#xD;
&#xD;
          5. Uterine size &gt;12cm or clinical suspicion that the uterus will not be able to be&#xD;
             removed vaginally.&#xD;
&#xD;
          6. Evidence of metastatic disease (imaging or histologically positive lymph nodes)&#xD;
&#xD;
          7. History of prior pelvic or abdominal radiotherapy&#xD;
&#xD;
          8. Prior malignancy within 5 years&#xD;
&#xD;
          9. Unable to withstand prolonged lithotomy or steep trendelenberg&#xD;
&#xD;
         10. Patient compliance and geographic proximity that do not allow adequate follow-up&#xD;
&#xD;
         11. Poorly controlled HIV defined as CD4 count &lt;500&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Bixel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Ohio State Unversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Klein, MEd</last_name>
    <phone>215-854-0770</phone>
    <email>jklein@gog.org</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

